NeuroPace will present at the Leerink Partners 2025 Global Healthcare Conference on March 10, 2025, in Miami, FL.
Quiver AI Summary
NeuroPace, Inc., a medical device company dedicated to improving the lives of those with epilepsy, announced that its management will present at the Leerink Partners 2025 Global Healthcare Conference on March 10, 2025, in Miami, FL, at 4:20 PM ET. During the conference, they will also conduct investor meetings. The presentation will be available for live streaming, with a replay accessible for two weeks afterward on NeuroPace's Investor website. NeuroPace is known for its innovative RNS System, the first brain-responsive platform that provides personalized treatment to manage seizures in patients with drug-resistant epilepsy, potentially benefiting other brain disorder patients as well.
Potential Positives
- NeuroPace is positioned to highlight its innovative RNS System at a major healthcare conference, increasing visibility among investors and industry leaders.
- The presentation and investor meetings provide NeuroPace an opportunity to engage directly with stakeholders, potentially attracting interest and investment.
- The company's focus on transforming the lives of people with epilepsy through its unique technology underscores its commitment to addressing significant healthcare needs, which is appealing to investors and partners.
- Accessibility of the presentation via live webcast and subsequent replay enhances transparency and outreach, allowing a broader audience to engage with the company's vision and advancements.
Potential Negatives
- None
FAQ
What is NeuroPace, Inc. known for?
NeuroPace, Inc. is a medical device company focused on transforming the lives of people living with epilepsy through innovative treatment solutions.
When will NeuroPace present at the Leerink Partners Conference?
NeuroPace will present at the Leerink Partners 2025 Global Healthcare Conference on March 10, 2025, at 4:20pm ET.
How can I access the NeuroPace presentation?
The presentation will be accessible via live webcast, and a replay will be available for two weeks on their Investor website.
What is the RNS System by NeuroPace?
The RNS System is the first commercially available brain-responsive platform that delivers personalized, real-time treatment for epilepsy at the seizure source.
How does NeuroPace improve outcomes for epilepsy patients?
NeuroPace's innovative RNS System offers a more personalized solution for patients with drug-resistant epilepsy, potentially improving their quality of life.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NPCE Insider Trading Activity
$NPCE insiders have traded $NPCE stock on the open market 33 times in the past 6 months. Of those trades, 0 have been purchases and 33 have been sales.
Here’s a breakdown of recent trading of $NPCE stock by insiders over the last 6 months:
- LTD. KCK has made 0 purchases and 29 sales selling 5,589,459 shares for an estimated $51,390,697.
- MARTHA MORRELL (CHIEF MEDICAL OFFICER) has made 0 purchases and 4 sales selling 81,834 shares for an estimated $1,127,376.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NPCE Hedge Fund Activity
We have seen 34 institutional investors add shares of $NPCE stock to their portfolio, and 21 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KCK LTD. removed 350,266 shares (-6.2%) from their portfolio in Q4 2024, for an estimated $3,919,476
- KENT LAKE PR LLC added 232,555 shares (+18.6%) to their portfolio in Q4 2024, for an estimated $2,602,290
- ARMISTICE CAPITAL, LLC added 112,614 shares (+23.5%) to their portfolio in Q4 2024, for an estimated $1,260,150
- JANE STREET GROUP, LLC added 100,095 shares (+inf%) to their portfolio in Q4 2024, for an estimated $1,120,063
- MILLENNIUM MANAGEMENT LLC removed 96,782 shares (-13.1%) from their portfolio in Q4 2024, for an estimated $1,082,990
- VANGUARD GROUP INC added 62,099 shares (+6.2%) to their portfolio in Q4 2024, for an estimated $694,887
- JACOBS LEVY EQUITY MANAGEMENT, INC added 57,096 shares (+inf%) to their portfolio in Q4 2024, for an estimated $638,904
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MOUNTAIN VIEW, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink Partners 2025 Global Healthcare Conference at 4:20pm ET (1:20pm PT) on Monday, March 10, 2025, in Miami, FL. Management will also host investor meetings during the conference.
The presentation will be accessible via live webcast here . A webcast replay will be available for two weeks following the presentation in the Events section of NeuroPace’s Investor website at https://investors.neuropace.com .
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
[email protected]
